CD274 and non-small cell lung carcinoma: In the subset of NSCLC-BM (n = 1063) where concurrent PD-L1 IHC testing was performed, the frequency of PD-L1 expression (TPS ≥ 1) was 54.7% (581/1063) and PD-L1 high expression (TPS ≥ 50) was 29.3% (311/1063) (Fig. 3A,B).